Increasing the duration of decitabine to 10 days in induction does not appear to overcome resistance of TP53 mutation to venetoclax despite higher response rates at 85% (median OS was 5.8 months in ND and 4.5 months in R/R AML). Here, TP53 is linked to acute myeloid leukemia.